RNA medicines: which startup is ahead?
In our biotechnology market deck, you will find everything you need to understand the market
SUMMARY
Wave Life Sciences is currently ahead in RNA medicines, but Stoke Therapeutics owns the individual drug most capable of overturning that ranking.
The race has a narrow top two. Wave leads as a company because it combines direct human RNA editing, several clinical mechanisms, multiple organs, internal manufacturing, major partnerships and more than half a billion dollars in cash.
Stoke is the cleaner late-stage story. Zorevunersen has the longest patient follow-up, the strongest evidence of real clinical benefit and a fully enrolled Phase 3 trial, but almost all of Stoke’s value still rests on that one program.
Remix Therapeutics is the only company outside the top two with objective patient responses. Its oral drug has produced durable tumor shrinkage, though the decisive efficacy cohort still contains only seven biomarker-positive patients.
Human molecular proof and human benefit are not the same thing. Wave has shown that RNA editing can create large quantities of corrected protein in people; Stoke has shown the more persuasive patient-level outcomes so far.
The approval race is split. Wave may submit first through accelerated pathways, while Stoke has the more conventional and probably more credible approval package if its sham-controlled Phase 3 trial succeeds.
Delivery remains the quiet dividing line in the field. Liver-targeted GalNAc medicines are advancing fastest, but Wave’s experience across liver, muscle and the central nervous system gives it a broader practical base than most direct editing rivals.
Ascidian may have the most technically ambitious platform, replacing whole RNA exons rather than correcting one base. Roche and Lilly have validated the idea financially, but the platform still needs human efficacy.
Korro’s first clinical setback is one of the field’s most useful results. It showed that target engagement and detectable corrected protein can still fall far short of a useful medicine, which raises the evidentiary bar for AIRNA and every other preclinical editor.
Funding alone does not settle the ranking. Wave and Stoke have the cash and operating muscle for pivotal work, while Ascidian has used a much smaller equity base to attract unusually large partner commitments.
The next decisive events are straightforward: Stoke needs a positive EMPEROR readout, Wave needs regulatory traction and repeatable clinical effects across programs, and Remix needs more than seven patients. Until then, Wave leads the company race, Stoke may own the best asset, and Remix is the most credible disruptor.
This market map, featured in our biotechnology market deck, highlights top companies and startups in the biotechnology market
Which RNA medicine startups deserve to be in this race?
The serious RNA medicines race currently contains eight startups and development-stage biotechs with a direct claim to changing, repairing or controlling RNA inside patients.
We include Wave Life Sciences, Stoke Therapeutics, Remix Therapeutics, AIRNA, Ascidian Therapeutics, Korro Bio, CAMP4 Therapeutics and Shape Therapeutics. The group covers four related approaches: single-base RNA editing, exon replacement, splice or transcript control, and RNA-based increases in protein production. Wave and Stoke are publicly listed and older than the usual image of a startup. Both remain dependent on experimental medicines and compete with younger companies for capital, partners, scientists and trial sites.
We exclude Alnylam, Ionis and Moderna because they already operate as established commercial RNA companies. We also exclude DNA-editing companies that use RNA only as a delivery component, and messenger-RNA vaccine developers whose main challenge is different. The scope is broad enough to capture the real competitive field without turning every company that touches RNA into a direct rival.
Funding numbers require care. Private companies announce venture rounds, while listed companies raise money through IPOs, follow-on offerings and at-the-market programs. We use rounded, identifiable funding floors and exclude headline milestone payments that may never be earned.
| Startup | What it is building | Identifiable cumulative funding floor |
|---|---|---|
| Wave Life Sciences | RNA editing, RNA interference, exon skipping and allele-selective silencing | More than $800M across identifiable private and public financings; its latest large offering alone raised $350M |
| Stoke Therapeutics | Antisense medicines that increase protein output from a healthy gene copy | More than $400M across identifiable venture and public financings, excluding its $165M Biogen upfront payment |
| Remix Therapeutics | Oral small molecules that reprogram RNA processing and destroy selected mRNAs | $211M closed, plus a committed $100M financing tied to its planned public-company merger |
| AIRNA | ADAR-based RNA editing, starting with alpha-1 antitrypsin deficiency | $245M across its Series A and Series B |
| Ascidian Therapeutics | Large-scale RNA exon replacement, initially delivered with AAV vectors | $90M in disclosed equity funding |
| Korro Bio | Oligonucleotides that recruit natural ADAR enzymes to edit RNA | More than $200M in identifiable funding, followed by an $85M private placement during its pipeline reset |
| CAMP4 Therapeutics | Antisense medicines that target regulatory RNA to increase gene expression | More than $200M across private rounds, its IPO and a later private placement |
| Shape Therapeutics | Programmable RNA editing paired with engineered delivery systems | $147.5M across its Series A and Series B |
Is any RNA medicine startup clearly ahead today?
Wave Life Sciences currently leads the RNA medicines field overall, with Stoke Therapeutics close enough to take first place after one decisive Phase 3 result.
Wave has the widest clinical pipeline, the clearest human proof of direct RNA editing, several different RNA technologies and $544.6 million in cash at the end of its latest reported quarter. Stoke has a narrower pipeline but a more advanced medicine: zorevunersen has five years of patient experience and a fully enrolled global Phase 3 trial. Remix sits in a separate third position because its oral drug has produced real tumor responses, although the decisive cohort contains only seven patients.
The rest of the market remains much earlier. Ascidian and AIRNA have entered human testing without reporting patient efficacy. Korro is rebuilding after its first clinical editing drug produced too little corrected protein. CAMP4 is preparing to test its new lead medicine in patients. Shape has strong technology claims and a Roche partnership, but little recent evidence of clinical movement.
So the field is a narrow top two, one clinical challenger and five specialized platforms still trying to prove themselves.
| Current group | Startups | What separates the group |
|---|---|---|
| Overall leaders | Wave, Stoke | Human evidence, late-stage execution, strong cash positions and credible approval paths |
| Clinical challenger | Remix | Objective tumor responses and an oral product, with a very small efficacy sample |
| Early clinical specialists | Ascidian, AIRNA | First patients treated, but no convincing human efficacy yet |
| Rebuilding or pre-efficacy platforms | Korro, CAMP4, Shape | New candidates, regulatory preparation or preclinical technology without current patient benefit |
If you want more recent data on this point, please see our latest biotechnology market report.
As this chart shows, and as featured in our biotechnology market deck, search interest in biotech has been trending upward
Which RNA startup has helped real patients the most?
Among RNA medicine startups, Stoke Therapeutics currently has the strongest patient evidence: zorevunersen has shown sustained seizure reductions and broader functional improvement across the largest, longest-followed relevant group.
Zorevunersen changes RNA processing so the healthy copy of the SCN1A gene produces more NaV1.1 protein in children with Dravet syndrome. The early studies and their extensions involved 81 children and adolescents. Across different dosing groups and time windows, Stoke reported median major motor seizure reductions ranging from roughly 59% to 91%, alongside improvements in clinician assessments, adaptive behavior and quality of life. Some patients have now been followed for about five years, and the work has appeared in the New England Journal of Medicine rather than remaining only in company slides.
The evidence has an important weakness: the earlier studies were open-label and lacked a sham control. Seizure frequency naturally varies, and families who perceive benefits may remain in extension studies longer. Stoke’s Phase 3 trial now compares zorevunersen with a sham procedure and measures seizures at 28 weeks, followed by cognition and behavior at 52 weeks.
Wave has cleaner proof that its drug performs the intended molecular edit, while Remix has objective tumor shrinkage. Stoke leads on actual patient benefit.
Which RNA medicine startup is closest to an approval?
Stoke Therapeutics sits closest to a credible RNA medicine approval, although Wave Life Sciences could place an application before regulators sooner.
Stoke has completed enrollment of 162 patients in the main population of the global EMPEROR Phase 3 study. The company plans to begin a rolling US application in early 2027, report the main trial result later that year and complete the submission after the readout. About 50 patients had already passed the 28-week primary endpoint in the latest update, and no enrolled patient had discontinued treatment at that stage.
Wave is following a faster but less settled regulatory route with WVE-N531 for Duchenne muscular dystrophy. The company says it remains on track to file for accelerated approval during 2026, using dystrophin production as the key biomarker. Wave is also discussing whether corrected alpha-1 antitrypsin protein could support an accelerated path for WVE-006.
Remix has Fast Track status for REM-422 in adenoid cystic carcinoma and is expanding its Phase 2 work. A registration path could become unusually quick because these patients have no approved MYB-directed treatment, but seven biomarker-positive patients cannot support an approval argument by themselves.
Stoke leads on approval probability. Wave may still file first.
If you want more recent data on this point, please see our latest biotechnology market report.
This chart, featured in our biotechnology market deck, illustrates yearly venture capital funding for biotechnology startups
Has Wave Life Sciences really proved RNA editing works in people?
Wave Life Sciences has already proved that therapeutic RNA editing can create large amounts of corrected protein in people. The remaining test is whether that correction prevents lung and liver damage over time.
WVE-006 targets the faulty SERPINA1 transcript in people with the Pi*ZZ form of alpha-1 antitrypsin deficiency. These patients cannot naturally produce healthy wild-type M-AAT protein, so its appearance after dosing gives us a direct readout of successful editing. In the latest multidose results, corrected M-AAT represented 64% of total circulating AAT, harmful Z-AAT fell 71%, and total AAT reached 11.9 micromolar with biweekly dosing and 13.6 micromolar with monthly dosing. Editing remained detectable for at least three months after the last dose, with no liver toxicities reported in the available dataset.
Korro’s discontinued KRRO-110 offers a useful comparison. That drug also created some corrected protein in humans, showing that it reached the liver and engaged the target. The output was too low to support continued development, so Korro stopped the program, reduced staffing and rebuilt its AATD approach around a GalNAc-delivered candidate.
Wave currently produces corrected protein at a scale that resembles the healthier Pi*MZ biological state. AIRNA could eventually challenge that result, but its first patient was only recently dosed.
Is Stoke Therapeutics basically a one-drug company?
Stoke Therapeutics is currently a one-drug leader, and almost all of its competitive value rests on zorevunersen succeeding in Dravet syndrome.
Zorevunersen has years of patient follow-up, Breakthrough Therapy designation, a global Phase 3 program and a major Biogen partnership. Stoke’s next internal program, aimed at autosomal dominant optic atrophy, remains in early clinical development. TANGO has produced one highly credible medicine so far without yet repeating that success across several genes or organs.
Biogen paid $165 million upfront for rights outside the United States, Canada and Mexico, while Stoke retained the territories where it plans to build its own commercial business. Stoke also ended 2025 with about $391.7 million in cash and eligible partnership proceeds, enough to carry the company through the pivotal result and launch preparation.
A strong Phase 3 result would validate both zorevunersen and the wider TANGO platform. A weak result would leave Stoke without another advanced drug ready to protect its position. That is a lot to hang on one readout.
This chart, featured in our biotechnology market deck, looks at Vertex’s strategy in biotechnology
Could Remix become the most commercially attractive RNA medicine startup?
Remix Therapeutics could become the most commercially attractive RNA startup because REM-422 combines early tumor responses with the easiest product format in the field: an oral small molecule.
REM-422 changes MYB RNA processing so the transcript includes a poison exon and is destroyed. MYB drives adenoid cystic carcinoma but has resisted conventional protein-targeted drugs. At the recommended Phase 2 dose, three of seven biomarker-positive patients achieved confirmed partial responses, giving a reported response rate of 43%. All seven achieved disease control, and several responses lasted beyond one year, with some patients approaching two years on treatment.
The cohort remains tiny. One extra responder would move the rate from 43% to 57%; one fewer would cut it to 29%. The study is also open-label and has no randomized comparison. Later presentations have repeated the same seven-patient dataset, so they should be treated as one result rather than several validations. Seven patients is still seven patients.
Remix nevertheless has objective tumor shrinkage, confirmed target engagement in biopsies, an oral drug and Fast Track status in a cancer with no approved MYB-directed treatment. The company has also arranged a $100 million financing tied to its planned merger with Passage Bio.
A larger Phase 2 dataset could move Remix into the top two. For now, the drug looks stronger than the size of the evidence base.
If you want more recent data on this point, please see our latest biotechnology market report.
Which RNA startup has the strongest pipeline beyond one lead drug?
Wave Life Sciences owns the strongest RNA medicines pipeline because it has produced human data across several diseases and several ways of controlling RNA.
Wave’s active portfolio includes WVE-006 for alpha-1 antitrypsin deficiency, WVE-007 for obesity and cardiometabolic disease, WVE-N531 for Duchenne muscular dystrophy and WVE-003 for Huntington’s disease. WVE-008, which targets the PNPLA3 liver-disease variant, is moving toward clinical development. These programs edit a transcript, suppress a target, change splicing or selectively reduce a disease-causing allele.
The breadth is already producing separate human readouts. The AATD program has shown corrected protein. The obesity program has moved into Phase 2a after earlier data showed reductions in visceral fat and waist circumference following a single dose. The Duchenne program is approaching a planned filing, and the Huntington’s program has tested allele-selective lowering in the central nervous system.
Stoke has greater depth around one asset. Remix has two cancer studies around REM-422 but no second independently validated molecule. Ascidian has one internal clinical program plus broad partner-funded discovery. AIRNA, Korro, CAMP4 and Shape still derive most of their value from one lead candidate or a preclinical platform.
This chart, featured in our biotechnology market deck, illustrates yearly funding for biotechnology startups
Which RNA medicine startup has won the strongest pharma backing?
The largest pharma commitments belong to Ascidian Therapeutics, while Stoke has the strongest endorsement of a specific late-stage drug and Wave has the best repeated platform validation.
Ascidian received $42 million initially from Roche and can earn up to $1.8 billion in milestones for neurological RNA exon-editing programs. Lilly later signed a separate kidney-disease collaboration carrying potential payments of roughly $1.9 billion. Those milestone totals are conditional, but two large drugmakers have now chosen the same platform for different organs.
Wave’s GSK relationship provides a different type of evidence. GSK can advance as many as eight programs and selected a fourth program for development in early 2026. Wave may receive up to $2.8 billion across initiation, development, launch and commercial milestones. Repeated target selection carries more weight than a partnership announcement that never moves beyond its first research plan.
Stoke’s Biogen deal is the clearest product-level vote. Biogen paid $165 million upfront for international rights to zorevunersen and is helping run the global pivotal program. The agreement depends on one drug, but that drug already had years of patient data when Biogen committed.
| Startup | Major partner backing | What we learn from it |
|---|---|---|
| Ascidian | Roche: $42M initial and up to $1.8B; Lilly: up to about $1.9B | The largest external validation of platform breadth, spanning brain and kidney programs |
| Wave | GSK can advance up to eight programs; fourth program selected; up to $2.8B in milestones | A partner has repeatedly expanded its use of Wave’s platform |
| Stoke | Biogen paid $165M upfront and took international rights to zorevunersen | The strongest endorsement of a specific late-stage RNA medicine |
| Remix | Roche paid $30M upfront, later triggered another milestone, and offered up to $1B | Large pharma sees oral RNA processing as useful across multiple target classes |
| CAMP4 | GSK paid $17.5M upfront for regulatory-RNA discovery | Credible scientific interest, with a smaller financial commitment and earlier work |
| Shape | Roche offered up to roughly $3B under an older neuroscience and rare-disease agreement | Large theoretical value, but limited recent public evidence of program advancement |
Which RNA startup can reach difficult organs and still scale economically?
Wave Life Sciences currently reaches the widest range of tissues, but Remix Therapeutics has the simplest route to affordable manufacturing and distribution.
The liver is the easiest starting point for several RNA-editing companies because GalNAc conjugates bind receptors on liver cells. Wave, AIRNA and Korro all use this route in major programs. Success there says little about whether the same chemistry can reach muscle, the eye, the brain or solid tumors.
Stoke repeatedly delivers zorevunersen into cerebrospinal fluid through lumbar puncture and has observed clinical changes in children with a brain disorder. The procedure every four months is manageable for severe Dravet syndrome, although it would become a heavier burden in common neurological diseases.
Wave has active human programs in liver, muscle and the central nervous system. Its technologies differ by program, so one delivery system cannot take credit for every tissue. Even so, the company has more real-world experience crossing tissue boundaries than its direct platform peers.
Ascidian and Shape use engineered AAV vectors to carry RNA-editing instructions into difficult tissues. Ascidian has completed adult dose escalation with a subretinal treatment for Stargardt disease and arranged scalable manufacturing with Forge Biologics. AAV production remains expensive, specialized and difficult to repeat if immune responses prevent redosing.
Remix avoids many of these delivery and manufacturing constraints with an oral small molecule. REM-422 can use established chemical manufacturing and tablet supply chains without infusion centers, lumbar punctures or surgery. Treatment duration will determine the final economics, but Remix currently has the cleanest route to broad commercial scale.
If you want more recent data on this point, please see our latest biotechnology market report.
This chart, featured in our biotechnology market deck, compares the main business model options for biotech platform companies
Which RNA startup has enough money and operating muscle to deliver?
Only Wave and Stoke currently combine large cash reserves with the operating experience needed for pivotal trials and launch preparation; Ascidian has achieved the most partner leverage from a smaller equity base.
Wave reported $544.6 million in cash and equivalents, with a runway expected into the third quarter of 2028. That balance follows a $350 million public offering and supports several clinical programs at once. Wave also controls internal oligonucleotide manufacturing, reducing its dependence on outside capacity when formulations or doses change.
Stoke reported about $391.7 million at the end of 2025, before counting all eligible future Biogen proceeds. The company enrolled its main pivotal cohort in ten months and is already spending on US launch readiness.
Korro had $157.1 million after its latest private placement, and CAMP4 had $99.2 million before later contingent financing. Both expect runway into 2028, but each must use that capital to establish a new clinical lead. Cash duration carries limited value when the main drug lacks patient efficacy.
Ascidian reached human testing after disclosing $90 million in equity funding, then received $42 million upfront from Roche, signed Lilly and secured a specialist manufacturing partner. Remix has also turned $211 million of closed funding into an oral drug with objective responses and a financing route into 2028.
What can the leading RNA medicine startups do that rivals cannot easily copy?
Four RNA medicine startups have real technical advantages today: Wave, Stoke, Ascidian and Remix. Human data and execution knowledge provide stronger protection than broad platform claims.
Wave combines oligonucleotide chemistry, sequence design, stereochemistry, manufacturing and experience across editing, silencing and splicing. Another company can recruit the same natural ADAR enzyme, yet reproducing Wave’s dose-response work and clinical manufacturing process would take years.
Stoke’s advantage is partly biological and partly operational. TANGO targets unproductive RNA processing to increase protein from a healthy gene copy. Competitors could design another SCN1A antisense medicine, but they would lack Stoke’s patient history, trial-site network, caregiver relationships and regulatory experience in Dravet syndrome.
Ascidian has the most unusual editing range. Its platform aims to replace whole RNA exons and rewrite thousands of bases with one treatment. Single-base editors address one nucleotide, while traditional exon-skipping drugs usually remove a section. Safe human exon replacement could open diseases with many different mutations across a large gene.
Remix has built chemical libraries and screening systems for RNA structures that conventional drug discovery often ignores. Every successful compound should improve its map of which RNA-processing interactions can be drugged orally. The platform becomes harder to copy if REM-422 is followed by a second clinically active molecule.
This chart, featured in our biotechnology market deck, breaks down revenue across customer segments in the biotechnology market
Which RNA medicine startups are gaining ground right now?
Right now, Stoke has the strongest execution momentum, Remix has gained the most credibility from one clinical dataset, and Wave is advancing the largest number of meaningful programs.
Stoke completed enrollment of the 162-patient primary EMPEROR cohort in ten months. That pace is unusually strong for a rare pediatric disease trial involving genetic confirmation, multiple countries, lumbar punctures and a sham arm. The company now has a defined sequence of milestones leading toward a pivotal readout and rolling application.
Remix’s progress comes from one connected chain. The REM-422 response data supported Fast Track status, a larger Phase 2 program, a planned merger with Passage Bio and a $100 million concurrent financing. Each step depends on the same early oncology result, so we give the company credit for acceleration without counting one dataset several times.
Wave moved WVE-007 into Phase 2a after reporting encouraging body-composition changes, while its AATD and Duchenne programs continued toward regulatory decisions. Wave already delivered the field’s strongest direct human editing result. The obesity expansion now tests whether its chemistry can compete in a much larger commercial market.
AIRNA dosed its first patient in a global AATD study. Ascidian completed adult dose escalation, opened pediatric enrollment, signed Lilly and added scalable AAV manufacturing. CAMP4 filed to begin testing CMP-002 in SYNGAP1-related disorder. These are real advances, but none includes patient efficacy yet.
Korro is recovering rather than leading. The company raised $85 million, selected KRRO-111 after reporting more than 90% editing in animals and plans a separate clinical filing for KRRO-121. Shape has the weakest visible momentum because its public materials still emphasize older platform and partnership work rather than a current clinical candidate.
How much can we trust the RNA startup data?
We can trust the broad ranking of RNA medicine startups more than the precise gap between neighboring companies because the quality of disclosed evidence varies sharply.
Stoke offers the most externally scrutinized package. Its early work covers dozens of patients, includes years of follow-up and has been published in a major peer-reviewed medical journal. The open-label design leaves room for bias, which the sham-controlled Phase 3 trial should address.
Wave’s AATD result is company-reported, but the molecular endpoint is unusually hard to distort through expectation or measurement choice. Pi*ZZ patients do not naturally produce wild-type M-AAT. Detecting large quantities after dosing gives strong evidence that editing occurred. Clinical benefit over several years remains uncertain.
Remix’s tumor responses are objective scans, and target engagement was measured in biopsies. Seven selected patients create a wide statistical range, while the open-label trial cannot tell us how the drug compares with another active treatment. Repeated presentations of the same cohort improve visibility rather than sample size.
Evidence is much weaker for the earlier companies. AIRNA, Korro’s new candidates, CAMP4 and Shape rely heavily on internally generated animal data. Korro’s failed first program gives us the clearest warning: impressive preclinical editing can survive into humans at a level too small to make a useful medicine.
Funding comparisons are also uneven. Public companies disclose cash and financings every quarter, while private companies can keep cash balances, milestone receipts and spending private. We therefore give far more weight to human outcomes than to valuation or partnership headlines.
| Evidence tier | Companies | What we can say with confidence |
|---|---|---|
| Strongest clinical evidence | Stoke | Repeated patient outcomes exist; randomized confirmation remains pending |
| Strong molecular or objective early efficacy | Wave, Remix | The biological or tumor effect is real, while long-term clinical value and larger-cohort consistency remain open |
| Human dosing or safety without efficacy | Ascidian, AIRNA | The platforms have entered patients, but leadership claims are premature |
| Rebuilt or mainly preclinical evidence | Korro, CAMP4, Shape | Current rankings depend heavily on animal data, platform logic and financing capacity |
This chart, featured in our biotechnology market deck, shows how at-home genetic testing technology has evolved over time
Which RNA medicine startups are actually ahead?
Wave Life Sciences leads the RNA medicines race today, Stoke Therapeutics remains a close second, and Remix Therapeutics has become the strongest challenger outside that top pair.
Wave earns first place because it combines the field’s best direct human RNA-editing result with several clinical programs, several RNA mechanisms, internal manufacturing, major partnerships and more than half a billion dollars in cash. Stoke has a stronger single medicine and the clearest conventional approval path, but one pivotal result carries most of the company. Remix has the easiest product format and encouraging cancer efficacy, with evidence from too few patients to rank beside the top two yet.
A positive EMPEROR result that confirms seizure reduction and improves cognition or behavior would probably move Stoke into first place. Wave widens its lead if WVE-N531 reaches filing, WVE-006 gains a workable accelerated path, or WVE-007 reproduces its early body-composition effect in Phase 2a.
Remix needs a bigger ACC cohort to show that three responses were the start of a repeatable pattern. Ascidian needs visual or anatomical efficacy from ACDN-01. AIRNA needs human editing and corrected-protein data. Korro needs its redesigned candidates to avoid the shortfall that ended KRRO-110.
The answer is clear for now: Wave leads the company race, Stoke may own the best individual asset, and Remix has the clearest route to disrupting the top two.
| Rank | Startup | Why it ranks here now |
|---|---|---|
| 1 | Wave Life Sciences | Best overall mix of direct human editing, pipeline breadth, regulatory options, manufacturing control, partnerships and cash |
| 2 | Stoke Therapeutics | Strongest patient-benefit evidence and most credible pivotal program, with heavy dependence on zorevunersen |
| 3 | Remix Therapeutics | Objective and durable tumor responses plus an oral product, held back by a seven-patient efficacy cohort |
| 4 | Ascidian Therapeutics | First clinical exon editor, adult dose escalation completed and exceptional Roche and Lilly backing, without human efficacy yet |
| 5 | AIRNA | Well-funded direct challenger to Wave in AATD, now dosing patients but waiting for its first human readout |
| 6 | Korro Bio | Valuable human editing experience and enough cash to rebuild, after its first clinical program failed to produce enough corrected protein |
| 7 | CAMP4 Therapeutics | A credible protein-upregulation idea and a new SYNGAP1 trial path, with no current patient efficacy |
| 8 | Shape Therapeutics | Interesting CNS editing and delivery technology with Roche validation, but the weakest recent public evidence of clinical progress |
If you want more recent data on this point, please see our latest biotechnology market report.
OUR METHODOLOGY
This analysis asks which RNA medicine startup is actually ahead by separating company leadership into distinct questions: patient benefit, molecular proof, regulatory progress, pipeline breadth, delivery, commercial scalability, financing, partnerships, execution and recent momentum.
We assessed each dimension independently before forming the final ranking. A strong financing, partnership or platform claim did not automatically outweigh weak clinical evidence, and one promising clinical update did not erase concentration risk, delivery constraints or a thin pipeline.
Human evidence received the greatest weight. Randomized or peer-reviewed patient outcomes ranked above open-label observations; objective tumor responses and direct molecular editing readouts ranked above animal data; and first-patient dosing without efficacy was treated as an early milestone rather than proof of leadership.
The final ranking does not come from a mathematical scoring model or hidden weighting formula. It reflects the combined evidence across the Q&A, with more confidence placed in companies that have repeated human results, credible regulatory paths, enough cash to execute and advantages that are difficult to reproduce.
Funding figures are rounded identifiable floors rather than perfectly comparable totals. For public companies, we counted traceable private and public financings; for private companies, we used disclosed venture rounds. Potential milestone payments were excluded from funding totals because many may never be earned.
Key sources include Wave Life Sciences investor relations and SEC filings, Stoke Therapeutics investor relations, Remix Therapeutics news and publications, AIRNA news, Ascidian Therapeutics news, Korro Bio investor relations, CAMP4 Therapeutics news, and Shape Therapeutics news.
We also used ClinicalTrials.gov, SEC EDGAR, the New England Journal of Medicine, PubMed, and official updates from GSK, Biogen, Roche, Eli Lilly, Forge Biologics, and Passage Bio. Regulatory context came from the US Food and Drug Administration and the European Medicines Agency.
In our biotechnology market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- Gene editing: which startup is ahead?
- Who will deliver the first in-body CRISPR cure?
